Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Accumulated Expenses: 2019-2025

Historic Accumulated Expenses for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $28.1 million.

  • Allogene Therapeutics' Accumulated Expenses rose 3.95% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 3.95%. This contributed to the annual value of $30.1 million for FY2024, which is 3.38% down from last year.
  • As of Q3 2025, Allogene Therapeutics' Accumulated Expenses stood at $28.1 million, which was up 4.88% from $26.8 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Accumulated Expenses registered a high of $44.6 million during Q1 2023, and its lowest value of $24.4 million during Q2 2024.
  • Over the past 3 years, Allogene Therapeutics' median Accumulated Expenses value was $28.1 million (recorded in 2025), while the average stood at $30.7 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Accumulated Expenses spiked by 102.53% in 2021, and later crashed by 44.94% in 2024.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' Accumulated Expenses stood at $37.5 million in 2021, then increased by 5.99% to $39.7 million in 2022, then declined by 21.54% to $31.2 million in 2023, then fell by 3.38% to $30.1 million in 2024, then grew by 3.95% to $28.1 million in 2025.
  • Its last three reported values are $28.1 million in Q3 2025, $26.8 million for Q2 2025, and $25.0 million during Q1 2025.